Improved anticancer efficiency of Mitoxantrone by Curcumin loaded PLGA nanoparticles targeted with AS1411 aptamer

IF 1.4 Q4 NANOSCIENCE & NANOTECHNOLOGY
M. Hashemi, Zahra Haghgoo, Rezvan Yazdian-Robati, Sanaz Shahgordi, Zahra Salmasi, K. Abnous
{"title":"Improved anticancer efficiency of Mitoxantrone by Curcumin loaded PLGA nanoparticles targeted with AS1411 aptamer","authors":"M. Hashemi, Zahra Haghgoo, Rezvan Yazdian-Robati, Sanaz Shahgordi, Zahra Salmasi, K. Abnous","doi":"10.22038/NMJ.2021.08.03","DOIUrl":null,"url":null,"abstract":"Objective(s): Mitoxantrone (MTX) is one of the most commonly used chemotherapeutic agents for treatment of different cancers. However, prolonged treatment with MTX results in unwanted side effects and drug resistant cancer cells. Combination therapies and exploiting of targeted nanoparticles have the potential of improving the efficiency of drug treatment as well as reducing the side effects. Curcumin (CUR) is a biological molecules with anticancer property. In this study, we investigated whether targeted PLGA (Poly Lactic-co-Glycolic Acid)–CUR nanoparticles (NPs) can reinforce the effect of MTX on breast cancer cells.Materials and Methods: PLGA NPs containing CUR targeted with AS1411 aptamer were prepared by single emulsion evaporation method. Physicochemical properties of NPs were investigated. The cytotoxicity of non-targeted and targeted NPs along with MTX was evaluated on MCF7, 4T1 and L929 cell lines. Results: The results showed that PLGA-CUR NPs were synthetized with an average encapsulation efficiency of 66% with a mean size of 186±3.2 nm. The drug release of curcumin from these NPs within 72h was about 59% in neutral medium and 90% in acidic medium. Interestingly, the combined treatment with PLGA-CUR-Apt and MTX inhibited the cancer cell's proliferation significantly more than the non-targeted nanoparticles, CUR and MTX-treated group alone. Conclusion: These results suggest that targeted PLGA-CUR nanoparticles may consider as a potential therapeutic contender in improving the efficacy of MTX in Breast cancer therapy.","PeriodicalId":18933,"journal":{"name":"Nanomedicine Journal","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/NMJ.2021.08.03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NANOSCIENCE & NANOTECHNOLOGY","Score":null,"Total":0}
引用次数: 4

Abstract

Objective(s): Mitoxantrone (MTX) is one of the most commonly used chemotherapeutic agents for treatment of different cancers. However, prolonged treatment with MTX results in unwanted side effects and drug resistant cancer cells. Combination therapies and exploiting of targeted nanoparticles have the potential of improving the efficiency of drug treatment as well as reducing the side effects. Curcumin (CUR) is a biological molecules with anticancer property. In this study, we investigated whether targeted PLGA (Poly Lactic-co-Glycolic Acid)–CUR nanoparticles (NPs) can reinforce the effect of MTX on breast cancer cells.Materials and Methods: PLGA NPs containing CUR targeted with AS1411 aptamer were prepared by single emulsion evaporation method. Physicochemical properties of NPs were investigated. The cytotoxicity of non-targeted and targeted NPs along with MTX was evaluated on MCF7, 4T1 and L929 cell lines. Results: The results showed that PLGA-CUR NPs were synthetized with an average encapsulation efficiency of 66% with a mean size of 186±3.2 nm. The drug release of curcumin from these NPs within 72h was about 59% in neutral medium and 90% in acidic medium. Interestingly, the combined treatment with PLGA-CUR-Apt and MTX inhibited the cancer cell's proliferation significantly more than the non-targeted nanoparticles, CUR and MTX-treated group alone. Conclusion: These results suggest that targeted PLGA-CUR nanoparticles may consider as a potential therapeutic contender in improving the efficacy of MTX in Breast cancer therapy.
AS1411适配体靶向姜黄素负载PLGA纳米颗粒提高米托蒽醌的抗癌效果
目的:米托蒽醌(MTX)是治疗各种癌症最常用的化疗药物之一。然而,长期使用甲氨蝶呤治疗会导致不必要的副作用和耐药癌细胞。联合治疗和靶向纳米颗粒的开发具有提高药物治疗效率和减少副作用的潜力。姜黄素(Curcumin, CUR)是一种具有抗癌作用的生物分子。在这项研究中,我们研究了靶向PLGA(聚乳酸-羟基乙酸)-CUR纳米颗粒(NPs)是否可以增强MTX对乳腺癌细胞的作用。材料与方法:采用单乳液蒸发法制备以AS1411适配体为靶点的含CUR的PLGA NPs。研究了NPs的理化性质。在MCF7、4T1和L929细胞株上评价了非靶向和靶向NPs与MTX的细胞毒性。结果:合成的PLGA-CUR NPs包封率为66%,平均粒径为186±3.2 nm。在中性介质和酸性介质中,姜黄素在72h内的释放量分别为59%和90%。有趣的是,PLGA-CUR-Apt和MTX联合治疗对癌细胞增殖的抑制作用明显高于非靶向纳米颗粒、CUR和MTX单独治疗组。结论:这些结果表明靶向PLGA-CUR纳米颗粒可能被认为是提高MTX治疗乳腺癌疗效的潜在治疗竞争者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nanomedicine Journal
Nanomedicine Journal NANOSCIENCE & NANOTECHNOLOGY-
CiteScore
3.40
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信